Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is projected to generate revenue of 2.649 billion RMB in 2025, representing a decline of 5.8% year-over-year, with adjusted net profit expected to be 209 million RMB, down 49.7% year-over-year. The decline is attributed to an increase in the proportion of artificial insemination (IUI) affecting the number of egg retrieval cycles and pricing, along with zero markup on drug costs. However, there is a significant improvement expected in the second half of the year [1][5] - For 2026, the outlook is positive, driven by the implementation of the California commercial insurance law SB729, which is expected to catalyze a 38% year-over-year increase in cycle numbers in January and February. The new facility in Shenzhen is also expected to contribute positively, with a projected 18% year-over-year increase in cycle numbers [1][2] Summary by Sections Domestic Business - The revenue in the Greater Bay Area is expected to decline by 8.8% to 420 million RMB in 2025, primarily due to a higher proportion of lower-cost IUI cycles and delays in the relocation of the Shenzhen facility. However, a double-digit year-over-year growth is anticipated for the Shenzhen region in 2026, supported by a significant increase in capacity and higher customer pricing through premium services [2][3] Overseas Business - The HRC Fertility business in the U.S. is expected to benefit from the acceleration of commercial insurance coverage, with a projected revenue increase of 5.1% year-over-year in 2025. The implementation of SB729 is expected to enhance cycle numbers significantly, with a 38% year-over-year increase in January and February [3][4] Financial Forecast and Valuation - The company is expected to achieve adjusted EPS of 0.11 RMB in 2026, with a target price set at 3.25 HKD, reflecting a 26x PE ratio. This valuation considers the potential positive impact of the U.S. insurance coverage on revenue and pricing strategies [5][11]

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is expected to see a revenue of 2.649 billion RMB in 2025, a decrease of 5.8% year-over-year, with an adjusted net profit of 209 million RMB, down 49.7% year-over-year. The decline in revenue and profit is attributed to an increase in the proportion of artificial insemination (IUI) affecting the number of egg retrieval cycles and pricing, along with zero markup on drug costs. However, there is a significant improvement expected in the second half of the year [1][5] - For 2026, the company anticipates positive revenue growth driven by the implementation of the California commercial insurance law SB729, which is expected to increase cycle numbers by 38% year-over-year in January-February, and the new Shenzhen facility expected to contribute to an 18% year-over-year increase in cycle numbers [1][2] Summary by Sections Domestic Business - The revenue in the Greater Bay Area is projected to decline by 8.8% to 420 million RMB in 2025, primarily due to a higher proportion of lower-cost IUI cycles and delays in the relocation of the Shenzhen facility. However, for 2026, double-digit year-over-year growth is anticipated in the Shenzhen area due to significant capacity expansion and an expected increase in customer pricing through high-value services [2] Overseas Business - The HRC Fertility business in the U.S. is expected to benefit from the acceleration of commercial insurance coverage, with a revenue increase of 5.1% year-over-year in 2025. For 2026, both revenue and profitability are expected to improve significantly due to the SB729 law, which mandates insurance coverage for infertility diagnosis and treatment for larger companies [3] Steady Domestic Regions - The Chengdu region is expected to achieve positive revenue growth in 2026, supported by a 72.8% year-over-year increase in third-generation IVF cycles in 2025 and a rising proportion of high-value services. The Wuhan and Kunming regions are also projected to continue their steady expansion, with a target of over 5,000 cycles in 2026 [4] Profit Forecast and Valuation - The adjusted EPS for 2026-2028 is forecasted to be 0.11, 0.15, and 0.19 RMB respectively. The report assigns a 26x PE ratio for 2026, with a target price of 3.25 HKD, reflecting a premium over the average 17x PE of comparable companies [5][11]

Core Viewpoint - The report from CICC indicates an upward revision of the 2025 adjusted net profit forecast for Jinxin Fertility (01951) by 19% to 200 million yuan, while the 2026 forecast is lowered by 34% to 280 million yuan due to increased costs and changes in financial confirmation methods [1] Group 1: Financial Performance - The expected adjusted net profit for FY 2025 is approximately 200 million yuan, with a slight year-on-year decline in revenue, but a noticeable improvement in the second half of 2025 [1] - The company anticipates a recovery in the number of cycles starting from the second half of 2025, with a projected return to stable growth in 2026, expecting a growth rate of 5-10% in cycles and revenue [1][2] Group 2: Operational Improvements - The company has completed the handling of overseas asset impairment and other risk issues in the first half of 2025, with a significant improvement expected in the second half [2] - The company is focusing on core business operations, aiming to enhance market share and improve cash flow, with plans for a long-term stock buyback after reducing leverage [2]

Core Viewpoint - The company Jin Xin Reproductive (01951) is expected to see a recovery in its business in the second half of 2025, leading to a 19% increase in the adjusted net profit forecast for 2025 to 200 million yuan. However, the forecast for 2026 has been reduced by 34% to 280 million yuan due to increased costs and changes in financial confirmation methods, with a new forecast for 2027 set at 360 million yuan. The current stock price corresponds to a 24.8 times P/E ratio for 2026, and the target price has been lowered by 10% to 3.5 HKD, indicating a potential upside of 41.1% from the current level [1]. Group 1 - The adjusted net profit for fiscal year 2025 is projected to be approximately 200 million yuan, with a slight year-on-year decline in revenue expected [2]. - The company is anticipated to release its full-year results for 2025 in late March, with significant quarter-on-quarter improvements expected in the second half of 2025 [2]. Group 2 - The company is expected to see a gradual improvement in cycle numbers starting from the second half of 2025, with a return to stable growth in 2026, driven by the inclusion of assisted reproduction in health insurance policies [3]. - The overall cycle count for fiscal year 2025 is projected to decline by 1.4% year-on-year, a significant improvement compared to earlier periods [3]. Group 3 - The company has completed the handling of overseas asset impairment and other risk issues in the first half of 2025, with a notable improvement in the second half of the year [4]. - The adjusted net profit for fiscal year 2025 is expected to be around 200 million yuan, with EBITDA for 2026 projected to return to approximately 550 million yuan, indicating improvements in net profit and free cash flow [4]. Group 4 - The company is focusing on its core business and plans to enhance shareholder returns, with the new Shenzhen hospital expected to be fully operational by the first quarter of 2026 [5]. - The company is actively pursuing a restructuring of its U.S. HRC operations, with significant improvements and capital recovery expected by the end of the first half of 2026 [5].

Core Viewpoint - The report from CICC indicates a downward adjustment in the net profit forecast for Jinxin Fertility (01951) for 2025-2026 due to the impact of medical insurance payment policies and zero markup on medical consumables, with a projected decrease of 59.9% and 7.5% to 170 million and 417 million yuan respectively, while maintaining an "outperform" rating and a target price of HKD 3.90, suggesting a potential upside of 25.0% from the current closing price [1][2]. Group 1 - Jinxin Fertility's 1H25 performance fell short of market expectations, reporting revenue of 1.289 billion yuan, a year-on-year decline of 10.7%, and an adjusted net profit of 82 million yuan, down 67.0% year-on-year, primarily due to the impact of medical insurance policies on cycle numbers and average transaction prices, as well as the execution of zero markup policies on drug costs [2][3]. - The company anticipates a recovery in 2026 as the impact of policies stabilizes, with a gradual return of patients to IVF services, alongside the expected capacity release from the new building in Shenzhen [3][5]. Group 2 - In 1H25, the company faced short-term pressure due to policy impacts, with a significant increase in the proportion of artificial insemination (IUI) cycles affecting average transaction prices and profit margins [3]. - The company reported a net loss attributable to shareholders of 1.04 billion yuan in 1H25, largely due to impairment losses on goodwill and intangible assets in the US HRC amounting to 950 million yuan, and other investment impairments [4]. - The company plans to enhance shareholder returns through a long-term share buyback program after optimizing leverage, while also focusing on asset liability risk release and liquidity assurance through business restructuring and overseas loan renewals [4]. Group 3 - The company is focusing on key business areas as supportive policies for fertility are expected to continue, with the implementation of child-rearing subsidy policies likely to boost fertility intentions and benefit the overall growth of the assisted reproduction industry [5]. - The potential for policy support in egg freezing services is anticipated, as this area has stronger customer retention and longer service cycles, which could become a new growth driver for the company [5]. - The company expects to start relocating its Shenzhen facility in Q1 2026, aiming for a business capacity of 12,000-15,000 cycles, while continuing to strengthen core assisted reproduction services in Yunnan and Wuhan [5].